相关实验视频

Updated: Jun 7, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在患有小细胞/神经内分泌膀和前列腺癌的患者中,PD-1 阻塞加上基于西斯的化疗

Yiqian Gu¹, Ann Ly², Sara Rodriguez²

¹Department of Molecular, Cellular and Developmental Biology, University of California, Los Angeles, Los Angeles, CA, USA.

Cell reports. Medicine

|November 13, 2024

概括

布罗利祖马布与化疗相结合,在晚期小细胞膀和前列腺癌中显示出有前途的结果. 这种治疗提供了良好的生存率,并且耐受性很好,免疫细胞的变化可能预测患者的结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
生殖尿道癌症生殖尿道癌症

背景情况:

不同组织的小细胞神经内分泌癌 (SCNCs) 具有相似的生物学特征,包括对化疗的初始反应,随后是疾病的快速进展.
目前对晚期SCNC的治疗选择有限,这凸显了对新型治疗策略的需求.

研究的目的:

评估pembrolizumab与基化疗结合的安全性和疗效,用于患有III-IV期小细胞膀癌或小细胞/神经内分泌前列腺癌的患者.
探索T细胞受体谱系动态与临床结果 (包括无进展生存率) 之间的相关性.

主要方法:

一个1b期临床试验,涉及15名患有晚期小细胞膀癌 (1队列) 或小细胞/神经内分泌前列腺癌 (2队列) 的患者.
患者接受了pembrolizumab以及基于的化疗.
用单细胞和T细胞受体测序分析了连续的外周血液样本.

主要成果:

总体应答率 (ORR) 在第一队列中为43%,在第二队列中为57%.
两年总生存率 (OS) 在第一队列中为86%,在第二队列中为57%.
治疗一般耐受良好,40%的患者经历了3级或更高的不良事件,但没有发生与治疗相关的死亡或停止. T细胞的克隆扩张与无进展生存率相关.

结论:

布罗利祖马布与基于的化疗相结合,在患有晚期小细胞膀和前列腺癌的患者中显示出有前途的疗效和良好的安全性.
这些发现支持在更大的临床试验中进一步调查这种组合疗法和确定的T细胞谱系生物标志物.

关键词:

在PD-1封锁中.测序T细胞受体的测序临床试验临床试验临床试验临床试验临床试验免疫化学疗法免疫化学疗法神经内分泌前列腺癌前列腺癌.一个单细胞测序.小细胞膀癌是小细胞膀癌.小细胞癌,小细胞癌.

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...